Desvenlafaxine Succinate

A cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.

Also Known As:

2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate; 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol; Desvenlafaxine; O-desmethylvenlafaxine; O-desmethylvenlafaxine Succinate; O-desmethylvenlafaxine Succinate Monohydrate; Pristiq; WY 45,233; WY 45233; WY-45,233; WY-45233; 45,233, WY; 45233, WY; Monohydrate, O-desmethylvenlafaxine Succinate; O desmethylvenlafaxine; O desmethylvenlafaxine Succinate; O desmethylvenlafaxine Succinate Monohydrate; Succinate Monohydrate, O-desmethylvenlafaxine; Succinate, Desvenlafaxine; Succinate, O-desmethylvenlafaxine; WY45,233; WY45233

Networked: 193 relevant articles (41 outcomes, 76 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Tourian, Karen A: 26 articles (12/2016 - 11/2007)
2.	Guico-Pabia, Christine J: 22 articles (01/2016 - 10/2009)
3.	Boucher, Matthieu: 16 articles (01/2020 - 07/2014)
4.	Kornstein, Susan G: 15 articles (05/2016 - 01/2009)
5.	Soares, Claudio N: 10 articles (01/2020 - 10/2009)
6.	Thase, Michael E: 9 articles (02/2017 - 03/2009)
7.	Jiang, Qin: 9 articles (03/2011 - 12/2008)
8.	Fayyad, Rana: 8 articles (05/2016 - 12/2012)
9.	Hwang, Eunhee: 8 articles (11/2015 - 01/2013)
10.	Ninan, Philip T: 8 articles (01/2015 - 03/2009)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 10/01/2017 - "This post hoc analysis examined the time point at which clinically significant improvement in major depressive disorder (MDD) symptoms occurs with desvenlafaxine versus placebo. " 09/01/2014 - "Desvenlafaxine 50 mg/day significantly improved depressive symptoms compared with placebo in major depressive disorder patients with clinically relevant anxiety symptoms. " 12/01/2010 - "The efficacy of desvenlafaxine in treating major depressive disorder has been established. " 01/01/2020 - "Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder." 10/01/2019 - "Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials."
2.	Hot Flashes 07/01/2014 - "Desvenlafaxine was associated with a statistically significant reduction in the number and severity of daily moderate to severe hot flashes. " 01/01/2013 - "The meta-analysis suggests that treatment with desvenlafaxine 100 mg/day is associated with a significant reduction of moderate to severe hot flashes in postmenopausal women. " 01/01/2013 - "The aim of this study was to assess the 12-week efficacy of desvenlafaxine in treating moderate to severe vasomotor symptoms and the clinical relevance of improvements in postmenopausal women experiencing 50 or more moderate to severe hot flashes per week. " 07/01/2014 - "Desvenlafaxine is effective in the treatment of hot flashes but it is strongly associated with several adverse events and treatment discontinuation. " 11/01/2014 - "In clinical trials, it has been shown that desvenlafaxine reduced the frequency of hot flashes by 55 - 69%. "
3.	Pain (Aches) 10/01/2013 - "Short-term treatment with desvenlafaxine 50 mg/d was effective for the treatment of MDD in perimenopausal and postmenopausal women, with significant benefits on pain and functional outcomes evident as early as week 2. The safety and tolerability of desvenlafaxine were consistent with data in other populations. " 11/01/2007 - "Desvenlafaxine 200 mg/day was also significantly better than placebo on remission, Visual Analog Scale-Pain Intensity overall scores, and some Visual Analog Scale-Pain Intensity subscale scores. " 05/01/2017 - "Efficacy of desvenlafaxine for pain associated with FMS was not demonstrated." 11/01/2007 - "Desvenlafaxine 400 mg/day was significantly better than placebo on selected Visual Analog Scale-Pain Intensity subscale scores. " 05/01/2007 - "Visual Analog Scale-Pain Intensity results were significant for desvenlafaxine 100 mg/day versus placebo (p = .002), but not for the higher doses. "
4.	Nausea 06/01/2009 - "Desvenlafaxine was generally well tolerated in clinical trials; the most common adverse events were nausea, suicidal ideation, and changes in blood pressure and weight. " 09/01/2012 - "Standard indirect comparisons of both nausea and drop-outs identified potential differences between treatments, with the risk difference analyses suggesting a trend in favor of desvenlafaxine (nausea: relative risk 0.97; 0.77, 1.22; p = 0.80/RD -0.07; -0.12, -0.01; p = 0.02; and drop-outs due to adverse events: RR 0.86; 0.58, 1.29; p = 0.48/RD -0.04; -0.08, 0.00; p = 0.06). " 02/01/2012 - "Nausea was the most common adverse event with desvenlafaxine, was generally mild to moderate, and resolved within the first 2 weeks. " 02/01/2012 - "Primary endpoints included nausea incidence during the first 2 weeks of treatment and Discontinuation-Emergent Signs and Symptoms (DESS) Checklist total scores after taper weeks 1 and 2. Nausea incidence was significantly lower for the desvenlafaxine 25 mg/d (19%) and 50 mg/d (22.6%) titration regimens vs. no titration (35.2%; p=0.004 and p=0.035, respectively). " 10/01/2009 - "There were also increased minor side effects with desvenlafaxine, especially nausea, at the beginning of the treatment. "
5.	Drug-Related Side Effects and Adverse Reactions 01/01/2023 - "Pharmacokinetic parameters and adverse drug reaction (ADR) incidence obtained from six bioequivalence clinical trials (n = 98) evaluating desvenlafaxine formulations (five with single dose administration and one with multiple-dose administration) were analyzed. " 10/01/2019 - "To address the potential correlation between plasma concentrations of venlafaxine (VEN), its active metabolite O-desmethylvenlafaxine (ODVEN) and the active moiety, AM, (ODVEN + VEN) and adverse drug reactions (ADR) in a large naturalistic sample of in- and outpatients. " 02/01/2012 - "Adverse drug reactions were consistent with the known safety profile of desvenlafaxine, and significantly more women who received tibolone experienced episodes of bleeding compared with women who received desvenlafaxine or placebo." 02/01/2016 - "Risperidone/9-hydroxyrisperidone and N-desmethylvenlafaxine/O-desmethylvenlafaxine metabolic ratios >1 strongly predict individuals with poor metabolizer genotype, which could guide psychotropic drug treatment to avoid adverse drug reactions and to increase their therapeutic efficacy in patients prescribed these drugs."

Related Drugs and Biologics

1.	Desvenlafaxine Succinate
2.	Escitalopram
3.	Serotonin (5 Hydroxytryptamine)
4.	Norepinephrine (Noradrenaline)
5.	Venlafaxine Hydrochloride (Effexor)
6.	Vortioxetine
7.	Antidepressive Agents (Antidepressants)
8.	Paroxetine (Paxil)
9.	Citalopram
10.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Drug Therapy (Chemotherapy)
4.	Drug-Eluting Stents
5.	Polypharmacy